{
  "first_published_at": "2011-10-13", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON131928", 
  "title": "Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\"]}", 
  "_document_number": 134, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Dronedarone (Multaq&#9660;): cardiovascular, hepatic and pulmonary adverse events &#8211; new restrictions and monitoring requirements</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: October 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Following new evidence of cardiovascular, hepatic and pulmonary risk, a review of dronedarone has concluded that the benefits of treatment continue to outweigh the risks for the maintenance of sinus rhythm after successful cardioversion in a limited population of patients with paroxysmal or persistent atrial fibrillation; however, in light of safety concerns dronedarone should only be prescribed after other treatment options have been considered.&#160;To support safer use, patients should have their treatment reviewed at the next routine appointment to ensure that they remain eligible for dronedarone treatment according to the revised prescribing information, including new restrictions on use. Regular monitoring of cardiac, liver, and renal function during treatment is recommended<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">Dronedarone (Multaq&#9660;) is an antiarrhythmic agent available as a 400 mg film-coated tablet with a recommended dose of 400 mg twice daily.</p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h3\">Discontinuation of PALLAS study</font>&nbsp;</p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">The PALLAS study (Permanent Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy) had been investigating the potential clinical benefit of dronedarone (added to standard therapy) in patients older than 65 years with permanent atrial fibrillation in the reduction of:</p><ul>\r\n\t\t\t<li>\r\n\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">      Major cardiovascular (CV) events (ie, stroke, systemic arterial embolism, myocardial infarction, or cardiovascular death); or    </div>\r\n\t\t\t</li>\r\n\t\t\t<li>\r\n\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">      Unplanned cardiovascular hospitalisation or death from any cause    </div>\r\n\t\t\t</li></ul><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">The study was prematurely terminated in July 2011, when an interim analysis showed a significant excess of CV-related deaths, stroke, and hospitalisations due to CV events in the dronedarone group compared with placebo.</p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h3\">Review of risks and benefits</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">A Europe-wide review of the risks and benefits of treatment with dronedarone began in January 2011 because of concerns over reports of liver injury, including two cases of liver failure requiring transplantation. Product information was updated to recommend monthly liver-function testing for the first 6 months of treatment, and at 9 and 12 months after treatment initiation (see <font color=\"#000000\"><a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON108677\" target=\"_blank\">Drug Safety Update, Feb 2011</a>).</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">The review was extended to include CV and pulmonary safety after the premature termination of PALLAS and several reported cases of pulmonary injury which may be associated with dronedarone.</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">The review included data from PALLAS and postmarketing data for liver and pulmonary toxicity. The EU Committee for Medicinal Products for Human Use (CHMP) considered that the benefits of treatment now continue to outweigh the risks in a restricted patient population.</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h3\">Revised indication</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">CHMP recommended that dronedarone should now be used only for the maintenance of sinus rhythm after successful cardioversion in patients with paroxysmal or persistent atrial fibrillation (AF). Because of safety concerns, dronedarone should only be prescribed after alternative treatment options have been considered. Dronedarone should not be given to patients with left ventricular systolic dysfunction, or to patients with current or previous episodes of heart failure.</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">CHMP considered that treatment with dronedarone should be initiated and monitored only under specialist supervision. A number of further contraindications for use and recommendations for monitoring were also endorsed by CHMP.</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">&nbsp;</p><div class=\"dull_highlight\">\r\n\t\t\t<font class=\"h4\">Advice for healthcare professionals:</font>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><em>Contraindications:</em></font></p>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">Dronedarone is now contraindicated in patients with:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Unstable haemodynamic conditions</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">History of, or current, heart failure or left ventricular systolic dysfunction</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Permanent AF (ie, duration &ge;6 months or unknown, and attempts to restore sinus rhythm no longer considered by physician)</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Liver and lung toxicity related to previous use of amiodarone</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><em>Cardiovascular monitoring:</em></font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Patients should receive regular cardiac examinations, including an ECG at least every 6 months, to identify those who revert to AF. Discontinuation of dronedarone should be considered for these patients</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Discontinue treatment if the patient develops permanent AF</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Patients should be carefully evaluated for symptoms of heart failure during treatment</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Patients should be appropriately anticoagulated as per clinical AF guidelines. International Normalised Ratio (INR) should be closely monitored after initiating dronedarone in patients taking vitamin K antagonists as per the prescribing information for these products</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><em>Hepatic monitoring:</em></font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Liver-function tests should be done: before starting treatment with dronedarone; after 1 week of treatment; after 1 month of treatment; then every month for 6 months; at month 9; at month 12; and periodically thereafter</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><em>Renal monitoring:</em></font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Plasma creatinine values should be measured before and 7 days after initiation of dronedarone, and renal function should be monitored periodically afterwards. Discontinue treatment in any patients with further elevations of serum creatinine</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">Pulmonary monitoring:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Cases of interstitial lung disease, including pneumonitis and pulmonary fibrosis, have been reported in association with dronedarone. Onset of dyspnoea or non-productive cough may be related to pulmonary toxicity. If pulmonary toxicity is suspected during treatment, relevant lung examinations should be considered and treatment discontinued if confirmed</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">&nbsp;</p>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h4\">Advice for patients:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Patients should be advised to make a routine appointment to discuss their treatment with the treating physician, but should not stop taking dronedarone unless told to do so</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">&nbsp;</p>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h4\">Reporting of suspected adverse reactions:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Please report all suspected adverse reactions to dronedarone via the <a href=\"http://yellowcard.mhra.gov.uk/\" target=\"_blank\">Yellow Card Scheme</a></font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul></div><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">&nbsp;</p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h4\">Further information:</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">BNF section 2.3.2 <a href=\"http://bnf.org/bnf/bnf/current/2410.htm\" target=\"_blank\">Drugs for arrhythmias</a></font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><br><em>Article citation: Drug Safety Update Oct 2011, vol 5 issue 3: A1.</em><br></font><span style=\"FONT-FAMILY: Arial; FONT-SIZE: 11pt\"><span style=\"FONT-FAMILY: Arial; FONT-SIZE: 11pt\"><a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON108677\" target=\"_blank\"></a></span></span></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">Dronedarone (Multaq&#9660;) is an antiarrhythmic agent available as a 400 mg film-coated tablet with a recommended dose of 400 mg twice daily.</p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h3\">Discontinuation of PALLAS study</font>&#160;</p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">The PALLAS study (Permanent Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy) had been investigating the potential clinical benefit of dronedarone (added to standard therapy) in patients older than 65 years with permanent atrial fibrillation in the reduction of:</p><ul>\r\n\t\t\t<li>\r\n\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">      Major cardiovascular (CV) events (ie, stroke, systemic arterial embolism, myocardial infarction, or cardiovascular death); or    </div>\r\n\t\t\t</li>\r\n\t\t\t<li>\r\n\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">      Unplanned cardiovascular hospitalisation or death from any cause    </div>\r\n\t\t\t</li></ul><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">The study was prematurely terminated in July 2011, when an interim analysis showed a significant excess of CV-related deaths, stroke, and hospitalisations due to CV events in the dronedarone group compared with placebo.</p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h3\">Review of risks and benefits</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">A Europe-wide review of the risks and benefits of treatment with dronedarone began in January 2011 because of concerns over reports of liver injury, including two cases of liver failure requiring transplantation. Product information was updated to recommend monthly liver-function testing for the first 6 months of treatment, and at 9 and 12 months after treatment initiation (see <font color=\"#000000\"><a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON108677\" target=\"_blank\">Drug Safety Update, Feb 2011</a>).</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">The review was extended to include CV and pulmonary safety after the premature termination of PALLAS and several reported cases of pulmonary injury which may be associated with dronedarone.</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">The review included data from PALLAS and postmarketing data for liver and pulmonary toxicity. The EU Committee for Medicinal Products for Human Use (CHMP) considered that the benefits of treatment now continue to outweigh the risks in a restricted patient population.</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h3\">Revised indication</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">CHMP recommended that dronedarone should now be used only for the maintenance of sinus rhythm after successful cardioversion in patients with paroxysmal or persistent atrial fibrillation (AF). Because of safety concerns, dronedarone should only be prescribed after alternative treatment options have been considered. Dronedarone should not be given to patients with left ventricular systolic dysfunction, or to patients with current or previous episodes of heart failure.</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">CHMP considered that treatment with dronedarone should be initiated and monitored only under specialist supervision. A number of further contraindications for use and recommendations for monitoring were also endorsed by CHMP.</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">&#160;</p><div class=\"dull_highlight\">\r\n\t\t\t<font class=\"h4\">Advice for healthcare professionals:</font>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><em>Contraindications:</em></font></p>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">Dronedarone is now contraindicated in patients with:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Unstable haemodynamic conditions</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">History of, or current, heart failure or left ventricular systolic dysfunction</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Permanent AF (ie, duration &#8805;6 months or unknown, and attempts to restore sinus rhythm no longer considered by physician)</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Liver and lung toxicity related to previous use of amiodarone</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><em>Cardiovascular monitoring:</em></font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Patients should receive regular cardiac examinations, including an ECG at least every 6 months, to identify those who revert to AF. Discontinuation of dronedarone should be considered for these patients</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Discontinue treatment if the patient develops permanent AF</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Patients should be carefully evaluated for symptoms of heart failure during treatment</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Patients should be appropriately anticoagulated as per clinical AF guidelines. International Normalised Ratio (INR) should be closely monitored after initiating dronedarone in patients taking vitamin K antagonists as per the prescribing information for these products</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><em>Hepatic monitoring:</em></font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Liver-function tests should be done: before starting treatment with dronedarone; after 1 week of treatment; after 1 month of treatment; then every month for 6 months; at month 9; at month 12; and periodically thereafter</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><em>Renal monitoring:</em></font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Plasma creatinine values should be measured before and 7 days after initiation of dronedarone, and renal function should be monitored periodically afterwards. Discontinue treatment in any patients with further elevations of serum creatinine</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">Pulmonary monitoring:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Cases of interstitial lung disease, including pneumonitis and pulmonary fibrosis, have been reported in association with dronedarone. Onset of dyspnoea or non-productive cough may be related to pulmonary toxicity. If pulmonary toxicity is suspected during treatment, relevant lung examinations should be considered and treatment discontinued if confirmed</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">&#160;</p>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h4\">Advice for patients:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Patients should be advised to make a routine appointment to discuss their treatment with the treating physician, but should not stop taking dronedarone unless told to do so</font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">&#160;</p>\r\n\t\t\t<p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h4\">Reporting of suspected adverse reactions:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>\r\n\t\t\t\t\t<div class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">\r\n\t\t\t\t\t\t<font color=\"#000000\">Please report all suspected adverse reactions to dronedarone via the <a href=\"http://yellowcard.mhra.gov.uk/\" target=\"_blank\">Yellow Card Scheme</a></font>\r\n\t\t\t\t\t</div>\r\n\t\t\t\t</li>\r\n\t\t\t</ul></div><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\">&#160;</p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font class=\"h4\">Further information:</font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\">BNF section 2.3.2 <a href=\"http://bnf.org/bnf/bnf/current/2410.htm\" target=\"_blank\">Drugs for arrhythmias</a></font></p><p class=\"MsoNormal\" style=\"MARGIN: 0cm 0cm 0pt\"><font color=\"#000000\"><br><em>Article citation: Drug Safety Update Oct 2011, vol 5 issue 3: A1.</em><br></font><span style=\"FONT-FAMILY: Arial; FONT-SIZE: 11pt\"><span style=\"FONT-FAMILY: Arial; FONT-SIZE: 11pt\"><a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON108677\" target=\"_blank\"></a></span></span></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-10-01", 
  "date_last_modified": "2011-10-12", 
  "_assets": [], 
  "_item_id": 134, 
  "summary": "Following new evidence of cardiovascular, hepatic and pulmonary risk, a review of dronedarone has concluded that the benefits of treatment continue to outweigh the risks for the maintenance of sinus rhythm after successful cardioversion in a limited population of patients with paroxysmal or persistent atrial fibrillation; however, in light of safety concerns dronedarone should only be prescribed after other treatment options have been considered. To support safer use, patients should have their treatment reviewed at the next routine appointment to ensure that they remain eligible for dronedarone treatment according to the revised prescribing information, including new restrictions on use. Regular monitoring of cardiac, liver, and renal function during treatment is recommended", 
  "body": "Article date: October 2011\n\nDronedarone (Multaq▼) is an antiarrhythmic agent available as a 400 mg film-coated tablet with a recommended dose of 400 mg twice daily.\n\nDiscontinuation of PALLAS study \n\nThe PALLAS study (Permanent Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy) had been investigating the potential clinical benefit of dronedarone (added to standard therapy) in patients older than 65 years with permanent atrial fibrillation in the reduction of:  \n  \n  * Major cardiovascular (CV) events (ie, stroke, systemic arterial embolism, myocardial infarction, or cardiovascular death); or   \n  \n  * Unplanned cardiovascular hospitalisation or death from any cause   \n  \nThe study was prematurely terminated in July 2011, when an interim analysis showed a significant excess of CV-related deaths, stroke, and hospitalisations due to CV events in the dronedarone group compared with placebo.\n\nReview of risks and benefits\n\nA Europe-wide review of the risks and benefits of treatment with dronedarone began in January 2011 because of concerns over reports of liver injury, including two cases of liver failure requiring transplantation. Product information was updated to recommend monthly liver-function testing for the first 6 months of treatment, and at 9 and 12 months after treatment initiation (see [Drug Safety Update, Feb 2011](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON108677)).\n\nThe review was extended to include CV and pulmonary safety after the premature termination of PALLAS and several reported cases of pulmonary injury which may be associated with dronedarone.\n\nThe review included data from PALLAS and postmarketing data for liver and pulmonary toxicity. The EU Committee for Medicinal Products for Human Use (CHMP) considered that the benefits of treatment now continue to outweigh the risks in a restricted patient population.\n\nRevised indication\n\nCHMP recommended that dronedarone should now be used only for the maintenance of sinus rhythm after successful cardioversion in patients with paroxysmal or persistent atrial fibrillation (AF). Because of safety concerns, dronedarone should only be prescribed after alternative treatment options have been considered. Dronedarone should not be given to patients with left ventricular systolic dysfunction, or to patients with current or previous episodes of heart failure.\n\nCHMP considered that treatment with dronedarone should be initiated and monitored only under specialist supervision. A number of further contraindications for use and recommendations for monitoring were also endorsed by CHMP.\n\n \n\nAdvice for healthcare professionals:\n\nContraindications:\n\nDronedarone is now contraindicated in patients with:  \n  \n  * Unstable haemodynamic conditions  \n  \n  * History of, or current, heart failure or left ventricular systolic dysfunction  \n  \n  * Permanent AF (ie, duration ≥6 months or unknown, and attempts to restore sinus rhythm no longer considered by physician)  \n  \n  * Liver and lung toxicity related to previous use of amiodarone  \n  \nCardiovascular monitoring:  \n  \n  * Patients should receive regular cardiac examinations, including an ECG at least every 6 months, to identify those who revert to AF. Discontinuation of dronedarone should be considered for these patients  \n  \n  * Discontinue treatment if the patient develops permanent AF  \n  \n  * Patients should be carefully evaluated for symptoms of heart failure during treatment  \n  \n  * Patients should be appropriately anticoagulated as per clinical AF guidelines. International Normalised Ratio (INR) should be closely monitored after initiating dronedarone in patients taking vitamin K antagonists as per the prescribing information for these products  \n  \nHepatic monitoring:  \n  \n  * Liver-function tests should be done: before starting treatment with dronedarone; after 1 week of treatment; after 1 month of treatment; then every month for 6 months; at month 9; at month 12; and periodically thereafter  \n  \nRenal monitoring:  \n  \n  * Plasma creatinine values should be measured before and 7 days after initiation of dronedarone, and renal function should be monitored periodically afterwards. Discontinue treatment in any patients with further elevations of serum creatinine  \n  \nPulmonary monitoring:  \n  \n  * Cases of interstitial lung disease, including pneumonitis and pulmonary fibrosis, have been reported in association with dronedarone. Onset of dyspnoea or non-productive cough may be related to pulmonary toxicity. If pulmonary toxicity is suspected during treatment, relevant lung examinations should be considered and treatment discontinued if confirmed  \n  \n \n\nAdvice for patients:  \n  \n  * Patients should be advised to make a routine appointment to discuss their treatment with the treating physician, but should not stop taking dronedarone unless told to do so  \n  \n \n\nReporting of suspected adverse reactions:  \n  \n  * Please report all suspected adverse reactions to dronedarone via the [Yellow Card Scheme](http://yellowcard.mhra.gov.uk/)  \n  \n \n\nFurther information:\n\nBNF section 2.3.2 [Drugs for arrhythmias](http://bnf.org/bnf/bnf/current/2410.htm)\n\n  \nArticle citation: Drug Safety Update Oct 2011, vol 5 issue 3: A1.  \n\n"
}